Article

Financial Times on 2023-07-17 16:25

Dementia: Eli Lilly drug shown to slow Alzheimer’s progression

News, analysis and comment from the Financial Times, the worldʼs leading global business publication

Related news

FEli Lilly raises Alzheimer’s drug hopes ft.com
Washington
FAstraZeneca and Eli Lilly scrap Alzheimer’s trial ft.com
Eli Lilly & Co: Eli Lilly to seek US approval after Alzheimer’s drug trial success Financial Times
FEli Lilly chief seeks to recover from Alzheimer’s drug flop ft.com
South East Asia , China
Eli Lilly, AstraZeneca Drop Two Late-Stage Alzheimer’s Drug Trials wsj.com
FRoche and Eli Lilly drugs fail ‘inherited’ Alzheimer’s trial ft.com
FEli Lilly & Co: US regulator delays decision on Eli Lilly’s Alzheimer’s drug ft.com
Eli Lilly achieves hard-won success with Alzheimer’s and obesity drugs Financial Times
MEli Lilly CEO on slicing tips, potential weight problems drug, Alzheimer’s trial mvtelegraph.com
Lower Austria , Japan
MEli Lilly recruits black sufferers for Alzheimer’s examine, drugmakers try for range mvtelegraph.com
Tuskegee , Atlanta
IEli Lilly Q2 results: its Alzheimer’s drug could be ‘the biggest drug in history’invezz.com
Wall Street , China , North America
GAlzheimer’s Disease Diagnostic Market Impact and Recovery Analysis| Eli Lilly, TauRx, Alector galleonnews.com
FPharmaceuticals: Alzheimer’s drug failure deals blow to US drugmaker Eli Lilly ft.com
South East Asia , China
Eli Lilly Exploring Elanco Spinoff wsj.com
Eli Lilly CEO to Retire wsj.com
Eli Lilly Changes Goal of Alzheimer’s Trial wsj.com
Eli Lilly & Co: Eli Lilly to seek obesity drug approval that could disrupt weight loss market Financial Times
MEli Lilly hikes dividend by 8%marketwatch.com
Eli Lilly, Urban Outfitters skid; Deere climbs The Salt Lake Tribune
Wall Street , New York
CFO Moves: Eli Lilly, Dunkin’ Brands Group blogs.wsj.com
Wall Street